Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment
| Autor: | Alessio Squassina, Theodora Katsila, George P. Patrinos, Claudia Pisanu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Epigenomics
0301 basic medicine Bipolar Disorder RNA Untranslated Lithium (medication) Computational biology Biology Epigenesis Genetic 03 medical and health sciences 0302 clinical medicine Metabolomics Genetics medicine Humans Bipolar disorder Epigenetics Pharmacology Mood Disorders medicine.disease Non-coding RNA 030104 developmental biology Mood Mood disorders Lithium Compounds Molecular Medicine 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pharmacogenomics. 19:129-143 |
| ISSN: | 1744-8042 1462-2416 |
| Popis: | Mood stabilizers are the cornerstone in treatment of mood disorders, but their use is characterized by high interindividual variability. This feature has stimulated intensive research to identify predictive biomarkers of response and disentangle the molecular bases of their clinical efficacy. Nevertheless, findings from studies conducted so far have only explained a small proportion of the observed variability, suggesting that factors other than DNA variants could be involved. A growing body of research has been focusing on the role of epigenetics and metabolomics in response to mood stabilizers, especially lithium salts. Studies from these approaches have provided new insights into the molecular networks and processes involved in the mechanism of action of mood stabilizers, promoting a systems-level multiomics synergy. In this article, we reviewed the literature investigating the involvement of epigenetic mechanisms, noncoding RNAs and metabolomic modifications in bipolar disorder and the mechanism of action and clinical efficacy of mood stabilizers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|